Table 1.
Baseline demographic and clinical characteristics of patients with T1D treated with autologous non-myeloablative hematopoietic stem cell transplantation in two AHCST cohorts.
| Patient characteristics | |
|---|---|
| Number of patients included | n = 36 |
| Age (years ± SEM) | 22.4 ± 0.9 |
| Gender (M/F) | 27/9 |
| BMI (kg/m2 ± SEM) | 20.7 ± 0.5 |
| HbA1c (mmol/mol ± SEM) | 86.6 ± 6.4 |
| C-peptide (ng/ml ± SEM) | 0.73 ± 0.06 |
| Autoantibodies | (% of patients) |
| GAD | 86 |
| Other (IAA, IA-2A, ICA) | 17 |
| DKA or DK history | (% of patients) |
| No DKA/DK | 67 |
| DKA | 28 |
| DK | 5 |
T1D, type 1 diabetes; AHSCT, autologous hematopoietic stem and progenitor cell transplantation; BMI, body mass index; GAD, glutamic acid decarboxylase autoantibodies; ICA, islet cell cytoplasmic autoantibodies; IA-2A, insulinoma-2-associated autoantibodies; IAA, insulin autoantibodies; DKA, diabetic ketoacidosis; DK, diabetic ketosis.